Device Trial Radar · NCT02653755
The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer
Last checked: Nov 21, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
671
Actual
Start
Dec 15, 2015
Primary completion
May 15, 2030
Study completion May 15, 2030
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- NanoString Technologies, Inc.
- First posted
- Jan 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is a way of gaining new knowledge about whether patients can omit radiation treatment after undergoing a lumpectomy, also known as "breast conserving surgery". In this trial, we are attempting to identify which patients may not need radiation.
Conditions
- Breast Cancer Radiation
Interventions
ProsignaDevice
Transcriptional profile of 50 genes used for risk stratification.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Five-Year Risk of Local Regional Recurrence in the Ipsilateral Breast or Lymph Nodes in Women without Adjuvant RadiotherapyTime frame: 5 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Johns Hopkins
Baltimore, Maryland
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.